A Single-Center Experience With Phoenix Atherectomy System in Patients With Moderate to Heavily Calcified Femoropopliteal Lesions.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
05 2020
Historique:
received: 12 05 2019
revised: 11 08 2019
accepted: 19 08 2019
pubmed: 7 9 2019
medline: 5 11 2020
entrez: 7 9 2019
Statut: ppublish

Résumé

To evaluate efficacy and safety of a new rotational atherectomy (RA), the Phoenix Atherectomy™ System, for the treatment of de novo and re-stenotic or occlusions atherosclerotic moderate-heavily lesions of the femoro-popliteal axis. From January 2015 to August 2017, 52 patients with heavily calcified femoro-popliteal lesions causing severe stenosis or occlusions were enrolled in our center to be treated using Phoenix catheters. Primary endpoints of this study were acute efficacy and safety at 30 days. Secondary endpoints were freedom from restenosis and target lesion revascularization (TLR)/target vessel revascularization (TVR) at 1-, 6- and 12- months. The mean lesion length was 9.2 cm (range 5-23 cm). The lesions were located in superficial femoral artery (SFA) in 61.5% (Fig. 1-A), in popliteal artery in 21.1% and involved femoral-popliteal axis in 15.4%. A primary technical success was achieved in 51/52 patients, with an optimal working channel after RA alone. Using Kaplan-Meyer analysis, primary vessel patency rates at 1, 6 and 12 -months was 96.1%, 86.5% and 76.9% respectively. Assisted primary patency at 1, 6- and 12 -months was 100%, 90.3% and 86.5% respectively. Recanalisation with the Phoenix Atherectomy System is simple and safe, with a high technical success rate.

Identifiants

pubmed: 31488361
pii: S1553-8389(19)30492-0
doi: 10.1016/j.carrev.2019.08.019
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

676-681

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors declare no conflict of interest.

Auteurs

Roberto Gandini (R)

Department of Diagnostic and Molecular Imaging, Radiation Therapy and Interventional Radiology, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.

Giovanni Pratesi (G)

Vascular Surgery, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Stefano Merolla (S)

Department of Diagnostic and Molecular Imaging, Radiation Therapy and Interventional Radiology, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.

Jacopo Scaggiante (J)

Department of Diagnostic and Molecular Imaging, Radiation Therapy and Interventional Radiology, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.

Fabrizio Chegai (F)

Department of Diagnostic and Molecular Imaging, Radiation Therapy and Interventional Radiology, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy. Electronic address: fabrizio.chegai@hotmail.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH